LamassuBiotech
  • Company
    • Mission & History
    • Leadership & Key Collaborators
    • Partners
  • The Lamassu Method
  • Pipeline
    • SA53
    • RABI-767
  • Lamassu Pets
  • Investor Resources
    • Investor Resources
    • Events & Presentations
  • News
    • News Releases
    • Media Coverage
  • Contact Us

Tag: News

05/16/2024

NEOtrans blog: Biotech startup moving HQ to Cleveland

A partnership with the Cleveland Clinic has prompted a four-year-old biotech startup to relocate its headquarters to Cleveland from Durham, NC, one of the points of the Research Triangle. However, Lamassu...
READ THE ARTICLE
08/05/2020

Bio-IT World: Follow the Money: Cash for AI Models, Oncology, Hematology Therapies

Sema4 gets $121M to build dynamic models of human health and define optimal, individualized health trajectories. Glioblastoma, hematology, and acute pancreatitis all see new funding for therapy development. And AI-powered models net cash.    $1.5M:...
READ THE ARTICLE

Posts navigation

Newer posts

Recent Posts

  • Crain’s Cleveland Business: Former FDA leader appointed to Lamassu Biotech board of directors
  • FORMER FDA COMMISSIONER DR. STEPHEN HAHN JOINS LAMASSU BIOTECH BOARD OF DIRECTORS
  • Ohio State Launches Clinical Trial for Promising New Treatment for Acute Pancreatitis in Dogs
  • RBV Quarterly: CEO Insights: Dr Gabi Hanna, Lamassu Biotech
  • SA53 MDM2 Inhibitor: Lamassu Biotech Reports Significant Progress and Favorable Safety Profile in Phase 1/2a Clinical Trial

Recent Comments

No comments to show.

Archives

  • April 2026
  • March 2026
  • January 2026
  • November 2025
  • October 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • February 2025
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • April 2021
  • August 2020
  • March 2020

Categories

  • media
  • news
  • Uncategorized

Menu

  • Investor Resources
  • News Releases
  • Contact us

Questions?

1-919-246-3969

info@lamassubio.com

  • Privacy Statement
  • Terms Of Use
  • Accessibility
  • FCOI Policies